EVENTS | VIEW CALENDAR
THC vs. chemotherapy-induced nausea and vomiting
COSTA MESA, Calif.—Nemus Bioscience Inc. reports that it is moving forward with Catalent Pharma Solutions to advance development of a human-dosage suppository formulation of NB1222, the proprietary prodrug of tetrahydrocannabinol (THC). NB1222, also known as the prodrug THC-valine-hemisuccinate, is being developed for the treatment and management of chemotherapy-induced nausea and vomiting (CINV). NB1222 is synthetically manufactured and is not plant-derived.
“Nemus is looking forward to working with Catalent to complete this important milestone as the company prepares to advance the candidate therapy to human clinical trials,” said Dr. Brian Murphy, CEO and chief medical officer of Nemus. “In addition to the recognized antiemetic activity of cannabinoids, we feel a formulation that could provide reliable and predictable bioavailability and pharmacokinetics, could leverage other valuable physiological attributes associated with cannabinoids like appetite stimulation along with anxiolytic and pain mitigation properties in a patient population that could benefit from these activities.”
Dr. Aris Gennadios, president of Catalent Softgel Technologies commented, “We believe Catalent's softgel technology is a great delivery choice for NB1222. With the convenience that softgel can offer, combined with a lipid formulation to enhance bioavailability and help assure dose uniformity, we expect Nemus to be well positioned to pursue development of an efficacious drug product.”
"The global CINV market is a multibillion dollar opportunity with projected growth as populations live longer, increasing the likelihood of developing a malignancy over time,” added Murphy. "THC-val-HS now has a patent footprint in major markets worldwide and we look forward to also advancing this prodrug into formulation activity for the glaucoma indication using our candidate molecule, NB1111.”